CLAIMS

1. A compound of Formula (I)



Formula (I)

or a pharmaceutically acceptable salt or physiologically functional derivative thereof, wherein

p is 0;

n is 0;

A^1 is thienyl, optionally substituted with one or more R^3;

Y^1 is -C(O)-, -C(S)-, or a bond;

R^1 is H or alkyl, cycloalkyl, aryl, or heteroaryl, each of which may be optionally substituted with one or more R^3;

A^2 is (i) pyridyl, optionally substituted with one or more R^3; (ii) thienyl, optionally substituted with one or more R^3; or (iii) pyrrole, optionally substituted with one or more R^3;

each R^3 independently is OR^4, SR^4, hydroxyalkyl, hydroxyalkylamino, cycloalkyl, halogen, haloalkyl, haloalkoxy, NO_2, CN, $SO_2NR^4R^5$, $CO_2NR^4R^5$, COR^4, CO_2R^4, SO_2R^4, SO_3R^4, NR^4R^5, alkyl, aryl, aryl substituted with halogen, or heteroaryl;

each R^4 independently is H, alkyl, cycloalkyl, aryl, or heteroaryl; and

each R^5 independently is H, O-alkyl, O-aryl, alkyl, heteroaryl, or aryl.

2. A compound of Formula (I)



Formula (I)

or a pharmaceutically acceptable salt or physiologically functional derivative thereof, wherein

p is 0;

n is 1;

A^1 is alkyl, aryl, or heteroaryl, each optionally substituted with one or more R^3;

Y^1 is -C(O)-, -C(S)-, or a bond;

R^1 is H or alkyl, cycloalkyl, aryl, or heteroaryl, each of which may be optionally substituted with one or more R^3;

R^2 is H or alkyl, cycloalkyl, aryl, or heteroaryl, each of which may be optionally substituted with one or more R^3;

Y^2 is -C(O)- or -C(S)-;

A^2 is thienyl, optionally substituted with one or more R^3;

each R^3 independently is OR^4, SR^4, hydroxyalkyl, hydroxyalkylamino, cycloalkyl, halogen, haloalkyl, haloalkoxy, NO_2, CN, $SO_2NR^4R^5$, $CO_2NR^4R^5$, COR^4, CO_2R^4, SO_2R^4, SO_3R^4, NR^4R^5, alkyl, aryl, aryl substituted with halogen, or heteroaryl;

each R^4 independently is H, alkyl, cycloalkyl, aryl, or heteroaryl; and

each R^5 independently is H, O-alkyl, O-aryl, alkyl, heteroaryl, or aryl.

3. The compound of claim 2 wherein A^1 is alkyl, phenyl, pyrimidinyl, pyridinyl, furanyl, thienyl, benzothienyl, pyrrolopyridinyl, or



each of which may be optionally substituted with one or more R^3.

4. The compound of claim 3 where R^3 is C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, cycloalkyl, $-CO_2CH_3$, or $-CO_2CH_2CH_3$.

5. A compound of Formula (I)



Formula (I)

or a pharmaceutically acceptable salt or physiologically functional derivative thereof, wherein

p is 1;

n is 1;

R is H or alkyl, cycloalkyl, aryl, or heteroaryl, each of which may be optionally substituted with one or more R^3;

A^1 is alkyl, aryl, or heteroaryl, each optionally substituted with one or more R^3;

Y^1 is -C(O)-, -C(S)-, or a bond;

R^1 is H or alkyl, cycloalkyl, aryl, or heteroaryl, each of which may be optionally substituted with one or more R^3;

R^2 is H or alkyl, cycloalkyl, aryl, or heteroaryl, each of which may be optionally substituted with one or more R^3;

Y^2 is -C(O)- or -C(S)-;

A^2 is thienyl, optionally substituted with one or more R^3;

each R^3 independently is OR^4, SR^4, hydroxyalkyl, hydroxyalkylamino, cycloalkyl, halogen, haloalkyl, haloalkoxy, NO_2, CN, $SO_2NR^4R^5$, $CO_2NR^4R^5$, COR^4, CO_2R^4, SO_2R^4, SO_3R^4, NR^4R^5, alkyl, aryl, aryl substituted with halogen, or heteroaryl;

each R^4 independently is H, alkyl, cycloalkyl, aryl, or heteroaryl; and

each R^5 independently is H, O-alkyl, O-aryl, alkyl, heteroaryl, or aryl.

6. The compound of claim 5 wherein A^1 is C_{1-12} alkyl or phenyl, each optionally substituted with one or more R^3.

7. The compound of claim 1 wherein A^1 is thienyl substituted with C_{1-6} alkyl, halogen, or C_{1-6} alkoxy.

8. The compound of claim 2 wherein A^2 is thienyl substituted with C_{1-6} alkyl, halogen, or C_{1-6} alkoxy.

9. The compound of claim 5 wherein A^2 is thienyl substituted with C_{1-6} alkyl, halogen, or C_{1-6} alkoxy.

10. A method for inhibiting the production of a virulence factor comprising contact with a compound of claim 1.

11. A method for inhibiting the production of a virulence factor comprising contact with a compound of claim 2.

12. A method for inhibiting the production of a virulence factor comprising contact with a compound of claim 5.

13. The method of claim 10 for the treatment or prevention of bacterial damage or disease.

14. The method of claim 11 for the treatment or prevention of bacterial damage or disease.

15. The method of claim 12 for the treatment or prevention of bacterial damage or disease.

16. The method of claim 13 wherein the bacteria is *Pseudomonas aeruginosa* or *Burkholderia cepacia*.

17. The method of claim 14 wherein the bacteria is *Pseudomonas aeruginosa* or *Burkholderia cepacia*.

18. The method of claim 15 wherein the bacteria is *Pseudomonas aeruginosa* or *Burkholderia cepacia*.

19. A composition for inhibiting biofilm formation comprising a compound of claim 1.

20. A composition for inhibiting biofilm formation comprising a compound of claim 2.

21. A composition for inhibiting biofilm formation comprising a compound of claim 5.

22. A compound selected from



,



,



,



;


,


,


,


;


;


.



,



,



,



,



;



,


,


,


,


,


,


,


,


,


,


,


,


,



,



,



,



,



,



,


,


,


,


,


,


,


,


,


,


,


,


,


,





























,



,



,

or



;

or a pharmaceutically acceptable salt or physiologically acceptable derivative thereof.

23. A method for inhibiting the production of a virulence factor comprising contact with a compound of claim 22.

24. A composition for inhibiting biofilm formation comprising a compound of claim 22.